MBL Wealth LLC Takes Position in Pfizer Inc. $PFE

Key Points

• MBL Wealth LLC has acquired a new stake in Pfizer Inc., purchasing 12,670 shares valued at approximately $321,000 in the first quarter.
• Institutional investors collectively own 68.36% of Pfizer's stock, with notable increases in holdings reported by several hedge funds in the same quarter.
• Pfizer's recent quarterly earnings report showed earnings per share of $0.78, surpassing analyst expectations of $0.58, with revenues reaching $14.65 billion—a 10.3% year-over-year increase.

MBL Wealth LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,670 shares of the biopharmaceutical company's stock, valued at approximately $321,000.

Several other institutional investors have also modified their holdings of the company. Gould Capital LLC lifted its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the 1st quarter valued at approximately $28,000. North Capital Inc. purchased a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 3.8%

NYSE:PFE traded down $0.95 during mid-day trading on Friday, hitting $23.91. The company had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. The business has a fifty day simple moving average of $24.79 and a 200-day simple moving average of $24.30. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 earnings per share. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.